| Literature DB >> 31514445 |
Fathy El-Saied1, Bishoy El-Aarag2,3, Tarek Salem4, Ghada Said5, Shaden A M Khalifa6,7, Hesham R El-Seedi8,9,10,11.
Abstract
The current study aimed to synthesize new metal coordination complexes with potential biomedical applications. Metal complexes were prepared via the reaction of isatin-N(4)anti- pyrinethiosemicarbazone ligand 1 with Cu(II), Ni(II), Co(II), Zn(II), and Fe(III) ions. The obtained metal complexes 2-12 were characterized using elemental, spectral (1H-NMR, EPR, Mass, IR, UV-Vis) and thermal (TGA) techniques, as well as magnetic moment and molar conductance measurements. In addition, their geometries were studied using EPR and UV-Vis spectroscopy. To evaluate the in vivo anti-cancer activities of these complexes, the ligand 1 and its metal complexes 2, 7 and 9 were tested against solid tumors. The solid tumors were induced by subcutaneous (SC) injection of Ehrlich ascites carcinoma (EAC) cells in mice. The impact of the selected complexes on the reduction of tumor volume was determined. Also, the expression levels of vascular endothelial growth factor (VEGF) and cysteine aspartyl-specific protease-7 (caspase-7) in tumor and liver tissues of mice bearing EAC tumor were determined. Moreover, their effects on alanine transaminase (ALT), aspartate transaminase (AST), albumin, and glucose levels were measured. The results revealed that the tested compounds, especially complex 9, reduced tumor volume, inhibited the expression of VEGF, and induced the expression of caspase-7. Additionally, they restored the levels of ALT, AST, albumin, and glucose close to their normal levels. Taken together, our newly synthesized metal complexes are promising anti-cancer agents against solid tumors induced by EAC cells as supported by the inhibition of VEGF and induction of caspase-7.Entities:
Keywords: Ehrlich ascites carcinoma; VEGF; caspase-7; isatin-N(4)antipyrinethiosemicarbazone; metal complexes; tumor volume
Mesh:
Substances:
Year: 2019 PMID: 31514445 PMCID: PMC6766913 DOI: 10.3390/molecules24183313
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Chemical structures of metal complexes 2–12.
Analytical and physical data of the ligand 1 and its metal complexes 2–11.
| No. | Molar Ratio/Compound | Color | m.p. (°C) | F.W. | Yield% | Analysis (%)/Found (Calcd) | Molar Conductance | |||
|---|---|---|---|---|---|---|---|---|---|---|
| C | H | N | S | |||||||
|
| HL C20H18N6O2S | Yellow | 210–212 | 406.64 | 94 | 59.14(59) | 5.15(4.43) | 20.91(20.66) | 7.85(7.87) | - |
|
| HL+CuCl2(1:1),(2:1),(1:2) [CuLCl]·H2O | Deep brown | 238–240 | 522.6 | 79 | 46.0(46) | 4.1(3.64) | 16.3(16.10) | 6.88(6.13) | 10.0 |
|
| HL+CuBr2(1:1) [CuLBr]·3H2O | Brown | 250 | 602.5 | 89 | 38.81(39.83) | 3.54(3.82) | 15.02(13.94) | 5.03(5.31) | 37.9 |
|
| HL+Cu(NO3)2·3H2O (1:1)[Cu(NO3) L]·H2O | Brown | 247 | 548.5 | 80 | 43.4(43.5) | 3.29(3.5) | 18(17.9) | 6(5.8) | 34.3 |
|
| HL+Cu(OAc)2 (1:1) [Cu(OAc) L]·2H2O | Brown | 212–216 | 563.5 | 74 | 46.12(46.90) | 4.82(4.30) | 15.13 (14.9) | 5.1(5.7) | 11.9 |
|
| HL+Cu(ClO4)2(1:1) [Cu(ClO4)L]·2H2O | Brown | 250–252 | 604.5 | 91 | 38.92(39.7) | 3.75(3.48) | 14.67(13.91) | 5.18(5.29) | 70.32 |
|
| HL+CoCl2 (1:1) [CoClL]2·2H2O | Brown | 258-260 | 1036 | 66 | 47(46.33) | 4.17(3.7) | 17(16.21) | 6.4(6.18) | 47.9 |
|
| HL+Co(OAc)2 (1:1) [Co(OAc) L(H2O)]·4H2O | Brown | Over 300 | 614.5 | 75 | 42.96(41.9) | 5.3(5.04) | 14.2(13.7) | 4.87(5.2) | 4.6 |
|
| Hl+NiCl2 (1:1) [NiCl2(HL)2]·4H2O | Brown | 254–255 | 1014.9 | 84 | 46.84(47.3) | 4.94(4.33) | 16.95(16.55) | 5.89(6.3) | 13.5 |
|
| HL+Ni(OAc)2 (1:1) [Ni(OAc) L]·2H2O | Brown | Over 300 | 558.9 | 70 | 47.76(47.24) | 4.19(4.3) | 15. 6(15.03) | 6.71(5.78) | 2.6 |
|
| HL+Zn(OAc)2 (1:1) [ZnL2·H2O | Deep yellow | Over 300 | 912.2 | 69 | 51.9(52.6) | 3.7(4.2) | 18.8 (18.42) | 6.64 (7) | 1.4 |
|
| HL+FeCl3 (1:1) [FeCl2(HL)2]Cl·H2O | Deep green | 210–212 | 993.7 | 78 | 47.62(48.3) | 3.9(3.8) | 16.95(16.91) | 5.6(6.44) | 54.09 |
IR spectral bands (cm−1) for ligand 1 and its metal complexes 2–12 and their assignments.
| No. | Ligand/Complexes | ν(H2O) | ν(N4H) | ν(C=O) | ν(C=N) | ν(C=S) | ν(M-O) | ν(M-N) | ν(OAc/ClO4/NO3 |
|---|---|---|---|---|---|---|---|---|---|
|
| Ligand C20H18N6O2S | - | 3442, 3348, 3287, 3251, 3141 | 1738 a, 1645 b | 1688 a, 1623, 1595 | 881 | - | - | - |
|
| [CuClL]·2H2O] | 3395 | 3161, 3100 | 1702 a, 1645 b | 1616, 1539 | 808 | 632 | 498 | - |
|
| [CuBrL]·3H2O | 3446 | 3106 | 1695 a, 1643(sh) b | 1622, 1578 | - | 614 | 504 | - |
|
| [Cu (NO3) L]·H2O | 3425 | 3166 | 1703 a, 1645 b | 1620, 1539 | 808 | 638 | 586 | 1382–1462 |
|
| [Cu(OAc)L]·2H2O | 3417 | 3237 | 1680 a, 1645 b | 1560, 1525 | 847 | 595 | 503 | 1615, 1333 |
|
| [Cu(ClO4)L]·2H2O | 3428 | 3325, 3170 | 1628 a, 1645 b | 1568, 1516 | 838 | 631 | 505 | 1085, 1049 |
|
| [CoClL]2·2H2O | 3388 | 3150 | 1734 a, 1645 b | 1600, 1515 | 840 | 629 | 585 | - |
|
| [Co (OAc) L(H2O)]·4H2O | 3491, 3422 | 3196 | 1734 a, 1645 b | 1590, 1545 | 841 | 630 | 540 | 1619, 1372 |
|
| [NiCl2(HL)2]·4H2O | 3441 | 3280 | 1735 a, 1660 a, 1645 b. 1610 b | 1688, 1620 | 877 | 648 | 591 | - |
|
| [Ni(OAc) L]·2H2O | 3445 | 3310, 3200 | 1664 a (sh), 1640 b | 1580, 1540 | 829 | 590 | 503 | 1620, 1342 |
|
| [Zn L2]·2H2O | 3413 | 3223 | 1700 a, 1643 b | 1609 | 848 | 612 | 580 | - |
|
| [FeCl2(HL)2]Cl·H2O | 3429(s,br) | 3280 | 1737 a, 1700 a, 1645 b, 1610 a | 1685, 1620 | 881 | 589 | 512 | - |
a indigo moiety, b antipyrine moeity, -: indicates no value available.
The electronic absorption spectral bands (nm) and magnetic moments of ligand 1 and its metal complexes 2–12.
| No. | Compound | π→π* (nm) | n→π* | Charge Transfer | d→d Bands | µeff (β.M) |
|---|---|---|---|---|---|---|
|
| HL C20H18N6O2S | 268 | 280, 369 | - | ||
|
| [CuLCl]·2H2O | 291 | 310, 395 | 600, 672, 770 | 1.03 | |
|
| [CuLBr]·3H2O | 295 | 325, 445 | 580, 631 | 1.1 | |
|
| [Cu(NO3) L]·H2O | 270 | 310, 455 | 520, 574 | 675, 720 | 1 |
|
| [Cu(OAc) L]·2H2O | 270 | 310 | 560, 671 | 1.11 | |
|
| [Cu(ClO4)L]·2H2O | 270 | 363, 400 | 500(br), 770(br) | 1.6 | |
|
| [CoClL]2·2H2O | 260 | 318, 345 | 600, 675, 700 | 0.42 | |
|
| [Co(OAc) L(H2O)]·4H2O | 290 | 320 | 600, 675, 780 | 3.7 | |
|
| [NiCl2(HL)2]·4H2O | 290 | 310, 396 | 420 | 500 | - |
|
| [Ni (OAc) L]·2H2O | 291 | 305 | 567, 950 | 2.26 | |
|
| [ZnL2]·2H2O | 280 | 319, 396 | 480, 520(sh) | - | - |
|
| [FeCl2(HL)2]Cl·H2O | 270 | 300, 391 | 450 | 584 | 4.67 |
-: indicates no value available.
EPR spectral assignments and bonding parameters for Cu(II) complexes in polycrystalline state at 298 K.
| Parameter | Complex 2 | Complex 3 | Complex 4 | Complex 5 | Complex 6 |
|---|---|---|---|---|---|
| g‖ or g1 | 2.189 | 2.198 | 2.287 | g‖ = 2.21 | 2.25 |
| g⊥ or g2, g3 | 2.121, 2.057 | 2.079, 1.989 | 2.121, 1.977 | g⊥ = 2.038 | 2.12, 2.027 |
| g⊥ | 2.089 | 2.034 | 2.049 | 2.038 | 2.074 |
| gav | 2.12 | 2.125 | 2.128 | 2.095 | 2.132 |
| G | 2.12 | 5.82 | 5.86 | 5.53 | 3.38 |
| R | 0.94 | 0.76 | 0.87 | - | 0.72 |
| k‖2/k‖ | 0.419/0.647 | 0.468/0.684 | 0.637/0.798 | 0.424/0.651 | 0.554/0.744 |
| k⊥2/k⊥ | 0.722/0.850 | 0.29/0.539 | 0.391/0.625 | 0.248/0.498 | 0.137/0.370 |
| K2/k | 0.621/0.788 | 0.349/0.591 | 0.473/0.688 | 0.307/0.554 | 0.276/0.525 |
-: indicates no value available.
Thermal (TGA) data for metal complexes 2, 3, 5, and 7–12.
| No. | Complex | Temp. Range (°C) | Weight Loss Found (calc)% | Assignment | Residual’s Formula |
|---|---|---|---|---|---|
|
| [Cu(L)Cl]·H2O] | 30–120 | 4.10 (3.44) | Loss of water of hydration (1H2O) | [Cu(L)Cl] |
|
| [Cu(L)Br]·3H2O | 26–75 | 9.3(8.96) | Loss of water of hydration (3H2O) | [Cu(L)Br] |
|
| [Cu(L)OAc]·2H2O | 30–109 | 6.60(6.40) | Loss of water of hydration (2H2O) | [Cu(L)OAc] |
|
| [Co(L)Cl]2·2H2O | 45–145 | 4.20(3.50) | Loss of water of hydration (2H2O) | [Co(L)Cl]2 |
|
| [Co(L)OAc(H2O)]·4H2O | 27–80 | 11.30(11.73) | Loss of water of hydration (4H2O) | [Co(L)OAc (H2O)]·CoO + 3C |
|
| [Ni(HL)2Cl2]·4H2O | 42–133 | 7.50(7.10) | Loss of water of hydration (4H2O) | [Ni (HL)2Cl2]·NiO + 7C |
|
| [Ni2(L)2(OAc)2]·4H2O | 27–75 | 6.00(6.43) | Loss of water of hydration (4H2O) | [Ni2(L)2(OAc)2] |
|
| [Zn(L)2]·2H2O | 45–131 | 3.98(3.95) | Loss of water of hydration (2H2O) | [Zn(L2)]·ZnS + 7C |
|
| [Fe(HL)2Cl2]Cl·H2O | 55–160 | 1.60 (1.80) | Loss of water of hydration (1H2O) | [FeCl2(HL)2]Cl |
Effect of ligand 1 and its metal complexes 2, 7 and 9 on the volume of solid tumor.
| Groups | Tumor Volume (mm3) | Inhibition % |
|---|---|---|
| Tumor-bearing mice + DMSO | 334.8 ± 17.5 | - |
| Tumor-bearing mice + ligand | 212.2 ± 22 * | 36.6 |
| Tumor-bearing mice + complex | 112.2 ± 52 ** | 66.5 |
| Tumor-bearing mice + complex | 99.2 ± 17.9 ** | 70.37 |
| Tumor-bearing mice + complex | 82.6 ± 3.9 ** | 75.53 |
Data are presented as mean ± SEM. Significantly (* p < 0.01 and ** p < 0.001) different from mice bearing solid tumor treated with vehicle (DMSO). -: indicates no value available.
Effect of ligand 1 and its metal complexes 2, 7 and 9 on serum biochemical parameters of mice bearing solid tumor.
| Groups | ALT (U/L) | AST (U/L) | Albumin (g/dL) | Glucose (mg/dL) |
|---|---|---|---|---|
| Normal control | 39 ± 3.1 | 194 ± 35.1 | 3.3 ± 0.3 | 128 ± 8.8 |
| Solid tumor + DMSO | 77.8 ± 11.5 # | 438.6 ± 66.4 # | 2.5 ± 0.2 # | 80.2 ± 9.5 # |
| Solid tumor + ligand | 43.2 ± 9 * | 387 ± 45.6 * | 2.3 ± 0.3 | 86.4 ± 11.2 |
| Solid tumor + complex | 42.2 ± 5 * | 275.6 ± 60.9 * | 2.4 ± 0.2 | 122.2 ± 11.6 ** |
| Solid tumor + complex | 39.2 ± 7.9 * | 206.6 ± 54.3 ** | 2.5 ± 0.1 | 126 ± 9.6 *** |
| Solid tumor + complex | 36.6 ± 3.9 ** | 208 ± 51.2 ** | 2.7 ± 0.4 | 127.4 ± 13.5 ** |
Data are presented as mean ± SEM. ALT: alanine aminotransferase; AST: aspartate aminotransferase. Significantly (# p < 0.01) different from the normal mice (untreated) and significantly (* p < 0.05, ** p < 0.01, *** p < 0.001) different from mice bearing solid tumor treated with vehicle (DMSO).
Figure 2Effect of ligand 1 and its metal complexes 2, 7 and 9 on vascular endothelial growth factor (VEGF) expression in tumor tissues (A) and in liver tissues (B) of Ehrlich ascites carcinoma (EAC)-bearing mice. VEGF expression was determined by immunohostochemistry assay. VEGF expression was expressed as labeling index percentage. Data are expressed as mean ± SEM. Significantly (## p < 0.01) different from the normal mice and significantly (** p < 0.01) different from mice bearing solid tumor treated with vehicle (DMSO).
Figure 3Effect of ligand 1 and its metal complexes 2, 7 and 9 on cysteine aspartyl-specific protease-7 (caspase-7) expression in tumor tissues (A) and in liver tissues (B) of Ehrlich ascites carcinoma (EAC)-bearing mice. Caspase-7 expression was determined by immunohistochemistry assay. Caspase-7 expression was expressed as labeling index percentage. Data are expressed as mean ± SEM. Significantly (## p < 0.01) different from the normal mice and significantly (** p < 0.01 and *** p < 0.001) different from mice bearing solid tumor treated with vehicle (DMSO).
Scheme 1Preparation of S-methylantipyrine carbodithioate.
Scheme 2Preparation of N(4)-antipyrinylthiosemicarbazide.
Scheme 3Preparation of Isatin N(4)-antipyrine-thiosemicarbazide 1 (ligand).